[This Week's IPO] December First Week Demand Forecast and Subscription Schedule

[Asia Economy Reporter Jang Hyowon] In the first week of this month (December), KTB Network and RaemongRaein will conduct demand forecasting for institutional investors. ToolGen is preparing for a general subscription.

◆KTB Network= KTB Network, a key affiliate of KTB Financial Group, is a first-generation venture capital (VC) firm established in 1981 in Korea. It is the only VC among the early investors in Toss (Viva Republica) that still holds shares, and one of its major investees, RBW, is scheduled to go public in November. ToolGen, the top company by market capitalization on KONEX, has also passed the preliminary review for listing and is scheduled to transfer-list on KOSDAQ in December.

The scale of assets under management is KRW 1.1195 trillion, and it recorded a net profit of KRW 35.8 billion last year. The total number of shares offered in this public offering is 20 million. The desired public offering price range is KRW 5,800 to 7,200 per share, with a total public offering amount of approximately KRW 116 billion to 144 billion.

After conducting demand forecasting for institutional investors on November 29-30, the public offering price will be finalized, followed by subscription on December 6-7, and listing within December. The lead underwriter is Korea Investment & Securities.

◆RaemongRaein= Established in 2007, RaemongRaein primarily operates in drama-centered content production. Since its inception, it has produced and aired over 30 popular contents and exports them worldwide, including Asia and South America. Representative works include 'Sungkyunkwan Scandal,' 'Extraordinary You,' 'Lie After Lie,' and 'Birthcare Center.'

The maximum funds to be raised through this public offering are KRW 15.6 billion (based on the upper limit of the desired price range). The funds raised will mainly be used for IP acquisition, content production including dramas, writer contracts, and investment in content planning, development, and production.

The total number of shares offered is 1.2 million, with a desired public offering price range of KRW 11,500 to 13,000 per share. Demand forecasting will be conducted on December 2-3 to finalize the public offering price, followed by general subscription on December 7-8. The listing is scheduled for mid-December, with IBK Investment & Securities as the lead underwriter.

◆ToolGen= ToolGen holds the original patent for the CRISPR gene-editing technology, which won the Nobel Prize in Chemistry in 2020. Gene-editing technology allows modification of traits by correcting the nucleotide sequence of DNA that contains genetic information related to specific traits.

The total number of shares offered is 1 million, with a desired public offering price range of KRW 100,000 to 120,000 per share. Demand forecasting for institutional investors was conducted on November 25-26, and the final public offering price will be determined on November 30. General subscription will be accepted on December 2 and 3. The company is scheduled to be listed on the KOSDAQ market in early December, aiming to raise up to approximately KRW 120 billion based on the desired public offering price. The lead underwriter is Korea Investment & Securities.